drug · protein
carfilzomib
Marketedupdated 5mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and multiple myeloma and 12 investigational indications.
targets
26S proteasome
all catalysts(0)
nothing on the calendar yet
Trials studying carfilzomib
- phase2Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- phase22015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- phase3A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- phase2A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- phase2Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- phase2Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- phase3Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 20, 2027
106 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Aug 27, 2033patentUS 9493582*PED
- Aug 27, 2033patentUS 9493582*PED
- Aug 27, 2033patentUS 9493582*PED
- Feb 27, 2033formulationUS 9493582
- Feb 27, 2033formulationUS 9493582
- Feb 27, 2033formulationUS 9493582
- Apr 21, 2030patentUS RE47954*PED3.5y
- Apr 21, 2030patentUS RE47954*PED3.5y
- Apr 21, 2030patentUS RE47954*PED3.5y
- Oct 21, 2029method-of-use (U-3449)US RE479543.0y
- Oct 21, 2029method-of-use (U-3449)US RE479543.0y
- Oct 21, 2029method-of-use (U-3449)US RE479543.0y
- Jun 7, 2028patentUS 7737112*PED1.7y
- Jun 7, 2028patentUS 7737112*PED1.7y
- Jun 7, 2028patentUS 7737112*PED1.7y
- Dec 7, 2027formulationUS 77371121.2y
- Dec 7, 2027formulationUS 77371121.2y
- Dec 7, 2027formulationUS 77371121.2y
- Jan 20, 2027patentUS 7417042*PED106d
- Jan 20, 2027patentUS 7417042*PED106d
- Jan 20, 2027patentUS 7417042*PED106d
- Jul 20, 2026compositionUS 7417042
- Jul 20, 2026compositionUS 7417042
- Jul 20, 2026compositionUS 7417042
FDA exclusivities (6)
- Nov 22, 2028PEDPediatric (6mo bonus)2.1y
- Nov 22, 2028PEDPediatric (6mo bonus)2.1y
- Nov 22, 2028PEDPediatric (6mo bonus)2.1y
- May 22, 2028M-14Method (3y)1.6y
- May 22, 2028M-14Method (3y)1.6y
- May 22, 2028M-14Method (3y)1.6y
News(2)
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 1mo ago
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.biopharma_dive · 4mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that